NCT04647604View on ClinicalTrials.gov

Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 23, 2020

Primary Completion Date

January 5, 2021

Study Completion Date

July 7, 2021

Conditions
COVID-19
Interventions
DRUG

Omegaven®

A highly refined fish oil in an emulsion for infusion with purified egg phosphatides and glycerol.

DRUG

Sodium chloride

intravenously administered 2 mL/kg/day

Trial Locations (2)

Unknown

Karolinska Universitetssjuhuset, Stockholm

Södersjukhuset, Stockholm

All Listed Sponsors
lead

Karolinska University Hospital

OTHER

NCT04647604 - Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids - | Biotech Hunter | Biotech Hunter